Retatrutide Phase 2 Efficacy Data The phase 2 dose-ranging trial (ClinicalTrials.gov NCT04881760, published in the New England Journal of Medicine in 2023) enrolled 338 adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity, and randomized them to placebo or retatrutide 1 mg, 4 mg, 8 mg, or 12 mg weekly after a structured titration period of up to 24 weeks [1]
Working with a provider whose background is in gastrointestinal health can be particularly beneficial, since many of GLP-1s benefits and side effects affect the digestive tract
Incorporating Glutathione into Your Dog's Health Routine 3
Lifehacks: How to lower high Lp(a) levels So what do you do if you carry the risk alleles for high Lp(a)
This principle applies across the vast landscape of peptide research
injectable semaglutide in more detail to help you figure out the right option for you